Keywords: ucb, forecasts, 200m, keppra, sales, following, approval

UCB forecasts $200m Keppra sales

Article | 09 December 1999

Print This

Following US approval of UCB Pharma's Keppra (levetiracetam) foruse in epilepsy (Marketletter December 6), a spokesman for the firm has told ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in